Upregulation or mutation of EGFR has been associated with the progression of non-small cell lung carcinoma (NSCLC), pancreatic cancers, colorectal cancers, and glioblastomas, among other tumors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.